Successful establishment of an orthotopic hepatoblastoma in vivo model in nod/ltsz-scid il2rγnull mice

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Ellerkamp, Verena ^a   Armeanu Ebinger, Sorin ^a   Wenz, Julia ^a   Warmann, Steven W ^a   Schäfer, Juergen ^a   Ruck, Peter ^b   Fuchs, Joerg ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Institute for Pathology Leonberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; CD31 ANTIGEN; CYTOKERATIN 7; EPITHELIAL CELL ADHESION MOLECULE; KERATIN; KI 67 ANTIGEN; LUCIFERASE; PLASMID VECTOR; VIMENTIN; INTERLEUKIN 2 RECEPTOR GAMMA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; EXPERIMENTAL MODEL; FEMALE; GENETIC TRANSFECTION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPLENECTOMY; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; VASCULARIZATION; ANIMAL; DISEASE MODEL; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SPLEEN;

MUS;

ALPHA-FETOPROTEINS; ANIMALS; ANTIGENS, CD31; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HEPATOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; KI-67 ANTIGEN; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; SPLEEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051539693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023419     Document Type: Article

References (33)

1. Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, et al. (2004) Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 40: 411-421.
2. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, et al. (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361: 1662-1670.
3. Zsiros J, Maibach R, Shafford E, Brugieres L, Brock P, et al. (2010) Successful Treatment of Childhood High-Risk Hepatoblastoma With Dose-Intensive Multiagent Chemotherapy and Surgery: Final Results of the SIOPEL-3HR Study. J Clin Oncol Apr 20.
4. Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, et al. (2008) Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 26: 2379-2383.
5. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, et al. (1996) Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74: 809-818.
6. Doi I, (1976) Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 67: 1-10.
7. Tanaka M, Kawamura K, Fang M, Higashino K, Kishimoto S, et al. (1983) Production of fibronectin by HUH6 C15 cell line established from a human hepatoblastoma. Biochem Biophys Res Commun 1983 110: 837-841.
8. McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, et al. (2003) Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg 38: 308-314.
9. Warmann SW, Fuchs J, (2007) Drug resistance in hepatoblastoma. Curr Pharm Biotechnol 8: 93-97.
10. Fuchs J, Schmidt D, Pietsch T, Miller K, von Schweititz D, (1996) Successful transplantation of human hepatoblastoma into immunodeficient mice. J Pediatr Surg 31: 1241-1246.
11. Kerbel RS, Cornil I, Theodorescu D, (1991) Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. Cancer Metastasis Rev 10: 201-215.
12. Leduc EH, (1959) Metastasis of transplantable hepatomas from the spleen to the liver in mice. Cancer Res 19: 1091-1095.
13. Schnater JM, Bruder E, Bertschin S, Woodtli T, de Theije C, et al. (2006) Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice. J Hepatol 45: 377-386.
14. Schmitz V, Tirado-Ledo L, Tiemann K, Raskopf E, Heinicke T, et al. (2004) Establishment of an orthotopic tumour model for hepatocellular carcinoma and non-invasive in vivo tumour imaging by high resolution ultrasound in mice. J Hepatol 40: 787-791.
15. Kim YR, Yudina A, Figueiredo J, Reichardt W, Hu-Lowe D, et al. (2005) Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. Cancer Res 65: 9253-9260.
16. Westwood JA, Darcy PK, Mayura-Guru P, Sharkey J, Pegram HJ, et al. (2010) Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med 8: 42.
17. Alves F, Contag S, Missbach M, Kaspareit J, Nebendahl K, et al. (2001) An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas 23: 227-235.
18. Till H, Metzger R, Bergmann F, Haeberle B, Schaeffer K, et al. (2006) Tumor model for laparoscopy in pediatric oncology: subperitoneal inoculation of human hepatoblastoma cells in nude rats. Eur J Pediatr Surg 16: 231-234.
19. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-6489.
20. Men S, Hekimoglu B, Tuzun M, Arda IS, Pinar A, (1995) Unusual US and CT findings in hepatoblastoma: a case report. Pediatr Radiol 25: 507-508.
21. Yamazaki M, Ryu M, Okazumi S, Kondo F, Cho A, et al. (2004) Hepatoblastoma in an adult A case report and clinical review of literatures. Hepatol Res 30: 182-188.
22. Till H, Bergmann F, Metzger R, Haeberle B, Schaeffer K, et al. (2005) Videoscopic fluorescence diagnosis of peritoneal and thoracic metastases from human hepatoblastoma in nude rats. Surg Endosc 19: 1483-1486.
23. Chung E, Yamashita H, Au P, Tannous BA, Fukumura D, et al. (2009) Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS One 4: e8316.
24. Martiniova L, Kotys MS, Thomasson D, Schimel D, Lai EW, et al. (2009) Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI. J Magn Reson Imaging 29: 685-691.
25. Freimuth J, Gassler N, Moro N, Gunther RW, Trautwein C, et al. (2010) Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma. Mol Cancer 9: 94.
26. Pusztaszeri MP, Seelentag W, Bosman FT, (2006) Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 54: 385-395.
27. Armengol C, Cairo S, Fabre M, Buendia MA, (2009) Wnt signaling and hepatocarcinogenesis: The hepatoblastoma model. Int J Biochem Cell Biol, Epub ahead.
28. Yamaoka H, Ohtsu K, Sueda T, Yokoyama T, Hiyama E, (2006) Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol Rep 15: 551-556.
29. Nelson WJ, Nusse R, (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487.
30. MacDonald BT, Tamai K, He X, (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
31. Belnoue E, Guettier C, Kayibanda M, Le Rond S, Crain-Denoyelle AM, et al. (2004) Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy. J Immunol 173: 4882-4888.
32. Varga NL, Barcena A, Fomin ME, Muench MO, (2010) Detection of human hematopoietic stem cell engraftment in the livers of adult immunodeficient mice by an optimized flow cytometric method. Stem Cell Stud 1: e5.
33. Melder RJ, Munn LL, Stoll BR, Marecos EM, Baxter LT, et al. (2002) Systemic distribution and tumor localization of adoptively transferred lymphocytes in mice: comparison with physiologically based pharmacokinetic model. Neoplasia 4: 3-8.